Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1440 participants.

Also called NCT07748039

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,440 participants (planned count) (from the registry)
Sponsor
  • Yongjun Wang Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07748039
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07748039. Randomized; single masking; primary purpose treatment. Start 2026-10-16 (actual); primary completion 2029-03-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events
Acronym
TRACE- BRIDGE
Condition
Acute Ischemic Stroke
Condition
Large Vessel Occlusion
Condition
Anterior Circulation Brain Infarction
Intervention (Drug)
rhTNK-tPA (0.25mg/kg)
Intervention (Drug)
Reteplase 10 Units (U) plus a second dose of reteplase 10 U
Intervention (Procedure)
No thrombolysis (thrombectomy alone)
Lead sponsor
Yongjun Wang (class: other)

Record details

Record id
cardio:ct-nct07748039
Content hash
c245720dc1324fde7ac308acd77b2600c2547575ddb7b181c9fece99bbe60764